EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial

David G Vossler iD, Mark Kristof Farkas iD, Irina Poverennova, Masako Watanabe, Peter Conrath, Svetlana Dimova iD, Carrie McClung, Robert Roebling iD, Paulette Williams, Terence J O'Brien iD, EP0012 Study Group

Epilepsia · 2024

DOI: 10.1111/epi.18158 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Epilepsia, 2024. Verfasst von David G Vossler und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Lacosamide, Anticonvulsants, Epilepsy, Generalized, Drug Therapy, Combination. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to assess long‐term safety, tolerability, and efficacy of lacosamide (LCM) as adjunctive therapy for generalized onset tonic–clonic seizures (GTCS) in patients aged ≥4 years with idiopathic generalized epilepsy (IGE).

Methods

EP0012 (NCT02408549) was a phase 3, multicenter, open‐label extension (OLE) trial. Patients were enrolled from SP0982 (NCT02408523). Trial duration was ≥2 years (adults) and ≤5 years (children). The trial consisted of a treatment period, ≤4‐week taper period, and 30‐day safety follow‐up. Safety (primary) variables were incidence of treatment‐emergent adverse events (TEAEs), discontinuations due to TEAEs, incidence of onset of absence or myoclonic seizures, and increase in days with absence or myoclonic seizures per 28 days. Efficacy (secondary) variable was percent change in GTCS frequency per 28 days. Kaplan–Meier estimated retention rates and analyses by number of lifetime antiseizure medications (ASMs) were performed post hoc.

Results

Overall, 239 patients (mean age = 27.9 years, 56.1% female, 18.4% children) were enrolled and received ≥1 dose of LCM in this OLE (median treatment duration = 3.2 years); 157 (65.7%) completed the trial, and 82 (34.3%) discontinued. The most common reason for discontinuation (≥10%) was withdrawn consent (30 [12.6%]). Kaplan–Meier estimated retention rate was 87%, 72%, and 60% at 1, 3, and 5 years, respectively. Overall, 222 (92.9%) patients reported TEAEs; 19 (7.9%) discontinued due to TEAEs. Few patients had an increase in number of days with absence or myoclonic seizures, or incidence of new absence or myoclonic seizures. Median percent change in GTCS frequency per 28 days from the combined baseline was −88.6% (range = −100.0 to 465.4, n = 238). Post hoc analyses demonstrated small numerical differences between patients with 1, 2, and ≥3 lifetime ASMs. Significance The results support the use of long‐term adjunctive LCM for GTCS in patients with IGE. Long‐term adjunctive LCM was efficacious and well tolerated independent of the number of ASMs used before LCM initiation. Clinical trial registration: ClinicalTrials.gov : NCT02408549.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LacosamideAnticonvulsantsEpilepsy, GeneralizedDrug Therapy, CombinationHumansFemaleMaleAdultAdolescentChildYoung AdultMiddle AgedTreatment OutcomeChild, PreschoolSeizures

Stichwörter der Autor:innen

antiseizure medicationidiopathic generalized epilepsylong‐term retentionphase 3 trialprimary generalized epilepsytreatment‐emergent adverse events

Substanzen

LacosamideAnticonvulsants

Autor:innen und Institutionen

  • Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Pediatric Center, Semmelweis University, Budapest, Hungary.
  • Seredavin Regional Clinical Hospital, Samara, Russia.
  • Shinjuku Neuro Clinic and National Center of Neurology and Psychiatry, Tokyo, Japan.
  • UCB, Brussels, Belgium.
  • UCB, Morrisville, North Carolina, USA.

ORCID-Profile: David G Vossler, Mark Kristof Farkas, Svetlana Dimova, Robert Roebling, Terence J O'Brien

Förderung

  • UCB

Zitieren

APA

Vossler, D. G., Farkas, M. K., Poverennova, I., Watanabe, M., Conrath, P., Dimova, S., McClung, C., Roebling, R., Williams, P., O'Brien, T. J., & EP0012 Study Group (2024). Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial. Epilepsia. https://doi.org/10.1111/epi.18158

Vancouver

Vossler DG, Farkas MK, Poverennova I, Watanabe M, Conrath P, Dimova S, et al. Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial. Epilepsia. 2024. doi:10.1111/epi.18158

BibTeX
@article{Vossler2024,
  author = {Vossler, David G and Farkas, Mark Kristof and Poverennova, Irina and Watanabe, Masako and Conrath, Peter and Dimova, Svetlana and McClung, Carrie and Roebling, Robert and Williams, Paulette and O'Brien, Terence J and EP0012 Study Group, EP0012 Study Group},
  title = {Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial},
  journal = {Epilepsia},
  year = {2024},
  doi = {10.1111/epi.18158}
}
Kostenlos starten →